Virax Biolabs Total Risk Alpha
| VRAX Stock | | | USD 0.18 -0.01 -5.26% |
This module presents the Total Risk Alpha indicator for Virax Biolabs Group using available market inputs. The indicator computation uses normalized market activity data. Exchange-specific data schedules may affect the recency of readings. Virax Biolabs has a market cap of 2.85 M, ROE of -83.82%. Use
World Market Map to explore allocation context. Allocation data is presented for contextual reference. Allocation figures are based on reported position values. This includes a position in Virax Biolabs Group. The position sits inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in nation.
Virax Biolabs Group has current Total Risk Alpha of
-0.64. The total risk alpha measures the performance of an asset by comparing its returns with those of a selected benchmark portfolio.
Total Risk Alpha | = | RFR + (ER[b] - ER[a]) | x | STD[a] / STD[b] |
| = | -0.64 | |
| ER[a] | = | Expected return on investing in Virax Biolabs |
| ER[b] | = | Expected return on market index or selected benchmark |
| STD[a] | = | Standard Deviation of returns on Virax Biolabs |
| STD[b] | = | Standard Deviation of selected market or benchmark |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
Total Risk Alpha Peers Comparison
Total Risk Alpha Relative To Other Indicators
Virax Biolabs Group is rated
below average in total risk alpha among leading competitors. It is currently under evaluation in maximum drawdown among leading competitors .
The benchmark portfolio represents the market risk matched to the total risk of the stock ETF or fund.
Compare Virax Biolabs to Peers
Other Technical Indicators